NextCure Corp - NXTC Net earnings per share for the last four quarters

Official company branding of NextCure Corp (NXTC)

NextCure, Inc. (NXTC) is deploying its available capital toward costly R&D, which drives the trend of its YoY (ttm) EPS percentage growth. The current level of 63.80 serves as a key metric for this trend. Exclusive FIND patents provide a defensive moat for the business, although strict FDA oversight limits its maneuverability. Meanwhile, geopolitical tensions and sanctions are seriously hindering the international logistics of biomaterials and therapy certification.

NextCure (NXTC) Earnings per share for the last twelve months: for the period 02/11/2024 - 11/15/2026

NXTC (NextCure): analytical breakdowns and indicator data

- current price and projected stock value:
Price Performance Chart NextCure|NXTC - Analyst Consensus Forecast
- issuer market value details:
Market Capitalization NextCure Corporation|NXTC - Total Company Value
- book value of equity indicators:
Accounting Value per Share NextCure|NXTC - Company Book Value|Market Cap to Net Assets Ratio nextcure.com|NXTC - Cumulative Company Assets
- debt and liquidity data:
Total Debt to Capital NextCure, Inc.|NXTC - Long-Term Debt to Equity|Short-Term Debt to Capital Ratio nextcure.com|NXTC - Company Debts|Debts to Book Value NextCure|NXTC - Company Long-Term Liabilities|Short-Term Indebtedness NextCure|Intermediate Liquidity Ratio nextcure.com
- earnings and market multiples details:
NXTC - Net Profit|Expected Net Income NextCure, Inc.|NXTC - P/E Multiple|Projected Price to Earnings Ratio NextCure Corporation|NXTC - Price/Earnings to Growth Ratio|Business Value to Operating Income Before Depreciation NextCure Corp|NXTC - Operating profit EBITDA|Net earnings per share (EPS TTM) NextCure|NXTC - Earnings per share for the last twelve months|Year-over-year net earnings per share trend for the last twelve months nextcure.com|NXTC - Net earnings per share growth this year|Expected net earnings per share growth next year NextCure, Inc.
- revenue and sales details:
NXTC - Company Revenue|Company Revenue Forecast NextCure|NXTC - P/S Multiple|Market Cap to Future Revenue Ratio NextCure|NXTC - Revenue Growth YoY (Last 12 Months)
Initial company analysis:NXTC, NextCure Corp
Mass-produced product of nextcure.com

This indicator calculates the percentage change in rolling earnings per share over twelve months, eliminating time gaps between quarterly reports to identify real profitability trends. Analyzing the rolling annual growth of net income per share allows for the timely detection of asset overheating, which is critical for NextCure, Inc. (NXTC), as its market capitalization depends on future premium pricing for innovative antibodies.

Direct competitors

Earnings per share for the trailing year IBRX (ImmunityBio)|IMCR: Net earnings per share (EPS TTM)|JANX - Net earnings per share for the last four quarters|Earnings per share for the last twelve months arcusbio.com|Net earnings per share for the last 12 months zymeworks.com (ZYME)|Earnings per share for the last twelve months Tango Therapeutics Inc (TNGX)|Net earnings per share for the last 12 months Iovance IOVA|Immatics NV - Net earnings per share for the last 12 months|Net earnings per share (EPS TTM) Xencor Inc. XNCR|CMPX - Earnings per share for the last twelve months|REPL (replimune.com) - Earnings per share for the last 12 months|Lyell Pharma (LYEL) - Earnings per share for the last twelve months|Net earnings per one share for the last twelve months Innate Pharma, S.A. (IPHA)|Net earnings per share for the last 12 months PYXS|CGEN - Net earnings per share for the trailing year|Net earnings per share for the last 12 months IOBT (IO Biotech Corp)|Earnings per share for the last four quarters STRO|Net earnings per share (EPS TTM) INKT (MiNK Therapeutics)|Earnings per share for the trailing year HOWL|Immix - Net earnings per share (EPS TTM)|Net earnings per one share for the last twelve months ALX Oncology Holdings Inc.|CUE: Net earnings per share (EPS TTM)|PDS Biotech - Earnings per share for the trailing year|SONN (Sonnet BioTherapeutics Holdings Inc.) - Net earnings per share (EPS TTM)|Net earnings per share (EPS TTM) MAIA Biotech|Earnings per share for the last twelve months Liminatus Pharma LLC (LIMN)|LVTX: Earnings per one share for the last 12 months|Leap Therapeutics - Net earnings per share for the last 12 months|Intensity Tx (INTS) - Net earnings per one share for the last twelve months|SNSE - Earnings per share for the last twelve months|Theriva Biologics - Earnings per share for the last four quarters|Gritstone Bio (GRTS) - Earnings per share for the last twelve months|Net earnings per one share for the last twelve months Kineta, Inc. (KA)|Net earnings per share for the last 12 months NEXI|TSBX: Earnings per share for the trailing year|Net earnings per share (EPS TTM) VCNX|HARP: Earnings per one share for the last 12 months